T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer s Disease
Research Triangle Park, 04/20/2021 EQS Newswire - T3D Therapeutics, Inc. RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / April 20, 2021 / T3D Therapeutics, Inc. ( T3D ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer s disease (AD), announced today the initiation of dosing in a Phase 2 clinical study of neurometabolic regulator T3D-959 in patients with mild to moderate Alzheimer s disease, the PIONEER Study. T3D-959 is a small molecule, orally-delivered, brain-penetrating PPAR delta/gamma dual nuclear receptor agonist designed to improve both glucose and lipid metabolism dysfunctions present in AD, and other neurodegenerative disorders.
(0)
RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / April 20, 2021 / T3D Therapeutics, Inc. ( T3D ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer s disease (AD), announced today the initiation of dosing in a Phase 2 clinical study of neurometabolic regulator T3D-959 in patients with mild to moderate Alzheimer s disease, the PIONEER Study.
T3D-959 is a small molecule, orally-delivered, brain-penetrating PPAR delta/gamma dual nuclear receptor agonist designed to improve both glucose and lipid metabolism dysfunctions present in AD, and other neurodegenerative disorders.
The Phase 2 PIONEER trial has resumed after pausing and making study adaptations in response to the COVID-19 pandemic. The PIONEER trial will assess the longitudinal safety, tolerability, clinical efficacy and pharmacodynamics of T3D-959, as well as its effects on biomarkers of neurodegeneration.
EQS-News: T3D Th .
EQS-News: T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer s Disease
vom 20.04.2021, 13:01 Uhr
Bild: pixabay.com
T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer s Disease
Research Triangle Park, 04/20/2021 / 07:01, EST/EDT - EQS Newswire - T3D Therapeutics, Inc.
RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / April 20, 2021 / T3D Therapeutics, Inc. ( T3D ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer s disease (AD), announced today the initiation of dosing in a Phase 2 clinical study of neurometabolic regulator T3D-959 in patients with mild to moderate Alzheimer s disease, the PIONEER Study.
T3D Therapeutics, Inc : T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer s Disease phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.